Beta Bionics officer files to sell 5,641 shares

An officer of Beta Bionics filed a Rule 144 notice for a potential sale of 5,641 common shares valued at about $113,000.

Rhea-AI Filing Summary

Beta Bionics, Inc. (BBNX) received a Rule 144 notice from officer Sean Saint covering a proposed sale of common stock. The notice lists up to 5,641 shares of Beta Bionics common stock, acquired as an Equity Award on September 1, 2025, with an indicated aggregate market value of $113,258.79 and NASDAQ as the trading market.

Key Figures

Shares proposed for sale: 5,641 shares Aggregate market value: $113,258.79 Date of acquisition of shares: September 1, 2025 +1 more

4 metrics

Shares proposed for sale 5,641 shares Common stock covered by the Rule 144 notice

Aggregate market value $113,258.79 Value of the 5,641 shares listed in the Form 144

Date of acquisition of shares September 1, 2025 Acquisition date for the Equity Award shares to be sold

Number of shares from Equity Award 5,641 shares Shares acquired via Equity Award from the issuer

Key Terms

Rule 144, Equity Award, aggregate market value, Issuer

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Equity Award financial

"Common | 09/01/2025 | Equity Award | Issuer"

An equity award is a form of pay where a company gives employees, executives or other stakeholders the right to own or buy company shares—either immediately or after meeting certain conditions. Think of it like receiving slices of the company pie now or coupons to claim slices later; it matters to investors because it affects ownership dilution, executive incentives and reported compensation costs, and signals how management is being rewarded and retained.

aggregate market value financial

"Common | ... | 5641 | 113258.79 | 44989688"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

Issuer regulatory

"09/01/2025 | Equity Award | Issuer"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing reveal about Beta Bionics, Inc. (BBNX)?

The Form 144 shows an officer, Sean Saint, has filed notice of intent to sell up to 5,641 shares of Beta Bionics common stock under Rule 144, representing shares acquired via an Equity Award on September 1, 2025.

How many Beta Bionics (BBNX) shares are covered by this Rule 144 notice?

The notice covers up to 5,641 shares of Beta Bionics common stock. These shares are listed in the Form 144 securities information and securities-to-be-sold sections as the amount proposed for sale.

What is the aggregate market value of the Beta Bionics (BBNX) shares in this Form 144?

The Form 144 lists an aggregate market value of $113,258.79 for the 5,641 shares of Beta Bionics common stock proposed for sale, based on the pricing information provided in the filing’s securities information section.

How were the Beta Bionics (BBNX) shares in this Form 144 acquired?

The shares were acquired as an Equity Award. The Form 144 states that the 5,641 shares of Beta Bionics common stock proposed for sale were obtained through an equity award on September 1, 2025 from the issuer.

On which market are the Beta Bionics (BBNX) shares in this Form 144 intended to be sold?

The Form 144 indicates that the NASDAQ market is associated with the proposed sale of the 5,641 shares of Beta Bionics common stock, as shown in the securities information section.

Who is the person filing the Rule 144 notice for Beta Bionics (BBNX)?

The Rule 144 notice is filed for the account of Sean Saint, identified as an officer of Beta Bionics, Inc. The filing covers a potential sale of 5,641 shares of the company’s common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/03/2026 - 03:53 PM EDT Accepted by SEC EDGAR 09/03/2026 - 03:52 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002048593
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Beta Bionics Inc
SEC File Number	001-42491
Address of Issuer	11 HUGHES Irvine CALIFORNIA 92618
Phone	9494277785
Name of Person for Whose Account the Securities are To Be Sold	Sean Saint
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 6002 El Tordo 2nd FL PO Box 7297 Rancho Santa Fe CA 92067	5641	113258.79	44989688	09/03/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/01/2025	Equity Award	Issuer			5641	09/01/2025	Equity Award

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	09/03/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	09/05/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Sean Saint
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)